OPEN Foundation

OPEN Foundation

The Ethnopharmacology of Ayahuasca

EthnopharmacologyayahuascaEthnopharmacology is a relatively new science that studies the cultural aspects of substances (plants, animals, minerals) and their biological characteristics and activities. While investigating and identifying compounds and the various uses they have in indigenous and non-indigenous groups, this science is also involved in studying the bio-activity of these materials. Ethnopharmacology is connected with other ethno-sciences, especially ethnobotany, which studies the uses of plants by human groups and their chemical and biological aspects. Plant development is part of nature but also part of the human culture, since man has been selecting plant materials from millennia for their qualities and characteristics. Humans use plants to eat, to hunt, to build houses, for killing, and from the rich variety of uses man had been given to plants, some kinds of uses involves the magical. Ayahuasca, a psychoactive Amazonian plant preparation, had been and still is used within the context of the sacred, the religious, the divinatory and the therapeutic. Ayahuasca is an excellent bio-active material to be investigated from an ethnopharmacological point of view, since its various uses, in the past and in the present, by many different human groups and for a high diversity of objectives, warrant an interdisciplinary approach. Although many human groups have been using different kinds of flora for reaching and connecting with the sacred, the hallucinogenic botany seems to occupy a very special place in some cultures. The high relevance of these substances is evident in many human groups. In the present book, several authors present to us some of the uses that ayahuasca had and still has in indigenous, mestizo and urban groups. Also, other chapters illustrate the various uses that ayahuasca have in modern science. This pan-Amazonian brew is used actually not only in Brazil, Colombia, Peru or Ecuador, where indigenous groups have been using this plant preparation for centuries, but in North America, Europe and Asia, where non-indigenous groups have been using this brew for many years now. It is an attempt of the present work to try to show the rich diversity that exists around ayahuasca. Because ethnopharmacology involves social aspects of bio-active compounds, the two first articles of the book are made considering the anthropological, cultural and social aspects of ayahuasca. In the first article, Luis Eduardo Luna shows how ayahuasca is used by indigenous and mestizo populations and in the second article Sandra Lucia Goulart discusses the context of the Brazilian ayahuasca religions. Luna and Goulart illustrate the diversity of concepts and ideas that these groups have regarding ayahuasca, discuss concepts and practices of healing and disease in these groups, and compare the ways in which ayahuasca is experienced and explained in these groups. The next articles are about pharmacological aspects of ayahuasca, to complement the social and cultural aspects. On the third article, José Carlos Bouso and Jordi Riba describe the pharmacological and neuropsychiatric aspects of this Amazonian brew. Their work is based in many years of clinical trials with acute ayahuasca administration to healthy volunteers and also on the investigations regarding the possible consequences of the long term consumption of this centenary potion. On the fourth article, Paulo César Ribeiro Barbosa illustrates a case report of a person that has taken ayahuasca for the first time. The possible therapeutic effects of ayahuasca are investigated in the context of the acute and post-acute effects of the brew. On the fifth article, Flávia de Lima Osório and collaborators explore the therapeutic potentials of one of the main ayahuasca alkaloids – harmine – for the treatment of depression, and they also discuss the curative potentials of the brew itself in this psychological disequilibrium. Still on the pharmacological perspective, but also involving psychiatry, the last two articles talk about the possible interactions of ayahuasca and cannabis in humans. One of the articles, which was wrote by me, is a theoretical overview of the eventual interactions – positive, neutral, or negative – that can potentially happen when humans take ayahuasca and cannabis together. The last article, wrote by me and Rick J. Strassman, shows a case report of a young man that had psychotic episodes related directly to the consumption of ayahuasca and cannabis. It is the main intention of the present book to make accurate and easy information regarding as many as possible aspects of ayahuasca accessible to the public. It is hoped that this little book will bring light to an issue that, in many cases, is still debated in obscurity.

The Ethnopharmacology of Ayahuasca, door Rafael Guimarães dos Santos, Transworld Research Network, 99 pagina’s.

Dit boek kunt u op 3 manieren lezen:

    • Door hier de individuele PDFs van elk hoofdstuk te downmloaden.
    • Door het hier als een tijdschrift te lezen.
    • Door het hele bestand hier te lezen.

The Shulgin Index: v. 1: Psychedelic Phenethylamines and Related Compounds

shulgin_indexThe Shulgin Index is a comprehensive collection of the known psychedelic phenethylamines and related compounds. There are 126 main compounds with detailed physical properties, synthesis and analytical chemistry, biochemistry, pharmacological properties, and legal status. Fully referenced with over 2,000 citations. There are sub-tables of lesser-studied structural homologues and analogues, over 1300 total compounds covered. GCMS scans are included for 229 compounds. This book is an invaluable resource for researchers, physicians, chemists, and law enforcement.

The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds, door Alexander T. Shulgin, Tania Manning & Paul F. Daley, Transform Press, 811 pagina’s.

Koop dit boek via bookdepository.com en steun daarmee Stichting OPEN

The 5-HT2A/1A Agonist Psilocybin Disrupts Modal Object Completion Associated with Visual Hallucinations

Abstract

Background: Recent findings suggest that the serotonergic system and particularly the 5-HT2A/1A receptors are implicated in visual processing and possibly the pathophysiology of visual disturbances including hallucinations in schizophrenia and Parkinson’s disease.

Methods: To investigate the role of 5-HT2A/1A receptors in visual processing the effect of the hallucinogenic 5-HT2A/1A agonist psilocybin (125 and 250 μg/kg vs. placebo) on the spatiotemporal dynamics of modal object completion was assessed in normal volunteers (n = 17) using visual evoked potential recordings in conjunction with topographic-mapping and source analysis. These effects were then considered in relation to the subjective intensity of psilocybin-induced visual hallucinations quantified by psychometric measurement.

Results: Psilocybin dose-dependently decreased the N170 and, in contrast, slightly enhanced the P1 component selectively over occipital electrode sites. The decrease of the N170 was most apparent during the processing of incomplete object figures. Moreover, during the time period of the N170, the overall reduction of the activation in the right extrastriate and posterior parietal areas correlated positively with the intensity of visual hallucinations.

Conclusions: These results suggest a central role of the 5-HT2A/1A-receptors in the modulation of visual processing. Specifically, a reduced N170 component was identified as potentially reflecting a key process of 5-HT2A/1A receptor–mediated visual hallucinations and aberrant modal object completion potential.

Kometer, M., Cahn, B. R., Andel, D., Carter, O. L., & Vollenweider, F. X. (2011). The 5-HT2A/1A Agonist Psilocybin Disrupts Modal Object Completion Associated with Visual Hallucinations. Biological Psychiatry, 69, 399–406. http://dx.doi.org/10.1016/j.biopsych.2010.10.002
Link to full text

Start Your Own Religion: New York State’s Acid Churches

Abstract

This paper describes a radical and short-lived spiritual movement that emerged in New York State in the 1960s. With Dr. Timothy Leary as the figurehead, two of these psychedelic religions rose to brief cultural prominence in period of 1963–1968 when Leary and his communal group made their home in the small village of Millbrook, New York. Due to negative media attention and a subsequent law enforcement crackdown brought upon at least partially by the increasingly provocative stance of the leaders of these psychedelic groups, they were forced to flee the state by early 1968. This paper establishes the historical significance of New York State’s Acid Churches within the culture of the 1960s and draws the link to today’s Neopagan and New Age movements and the rebirth of the use of psychedelic substances within the modern scientific, psychological, and therapeutic communities.

Lander, D. R. (2011).  Start Your Own Religion: New York State’s Acid Churches. Nova Religio: The Journal of Alternative and Emergent Religions, 14(3), 64–80. http://dx.doi.org/10.1525/nr.2011.14.3.64
Link to full text

A Prehistoric Mural in Spain Depicting Neurotropic Psilocybe Mushrooms?

Abstract

The Selva Pascuala mural, a work of post-Paleolithic rock art in Spain, contains fungoid figures herein hypothesized to depict neurotropic fungi, especially Psilocybe hispanica, a species that occurs in a neighboring region. This hypothesis is based on features of these figures related to fungal morphology, along with ethnographic analogy, and shamanistic explanations of rock art. If correct, this interpretation would support inference of prehistoric utilization of this fungus in the region. The mural represents the first direct evidence for possible ritual use of Psilocybe in prehistoric Europe.

Akers, B. P., Ruiz, J. F., Piper, A., & Ruck, C. A. P. (2011). A Prehistoric Mural in Spain Depicting Neurotropic Psilocybe Mushrooms?. Economic Botany, 65(2), 1–8. http://dx.doi.org/10.1007/s12231-011-9152-5
Link to full text

Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs

Abstract

Aims: In field studies assessing cognitive function in illicit ecstasy users, there are several frequent confounding factors that might plausibly bias the findings toward an overestimate of ecstasy-induced neurocognitive toxicity. We designed an investigation seeking to minimize these possible sources of bias.

Design: We compared illicit ecstasy users and non-users while (1) excluding individuals with significant life-time exposure to other illicit drugs or alcohol; (2) requiring that all participants be members of the ‘rave’ subculture; and (3) testing all participants with breath, urine and hair samples at the time of evaluation to exclude possible surreptitious substance use. We compared groups with adjustment for age, gender, race/ethnicity, family-of-origin variables and childhood history of conduct disorder and attention deficit hyperactivity disorder. We provide significance levels without correction for multiple comparisons.
Setting: Field study.
Participants: Fifty-two illicit ecstasy users and 59 non-users, aged 18–45 years.
Measurements: Battery of 15 neuropsychological tests tapping a range of cognitive functions.
Findings: We found little evidence of decreased cognitive performance in ecstasy users, save for poorer strategic self-regulation, possibly reflecting increased impulsivity. However, this finding might have reflected a pre-morbid attribute of ecstasy users, rather than a residual neurotoxic effect of the drug. Conclusions In a study designed to minimize limitations found in many prior investigations, we failed to demonstrate marked residual cognitive effects in ecstasy users. This finding contrasts with many previous findings—including our own—and emphasizes the need for continued caution in interpreting field studies of cognitive function in illicit ecstasy users.
Halpern, J. H., Sherwood, A. R., Hudson, J. I., Gruber, S. Kozin, D., & Pope Jr., H. G. (2011). “Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs. Addiction, 106(4), 777-786. http://dx.doi.org/10.1111/j.1360-0443.2010.03252.x
Link to full text

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens

Abstract

Serotonergic hallucinogens produce profound changes in perception, mood, and cognition. These drugs include phenylalkylamines such as mescaline and 2,5-dimethoxy-4-methylamphetamine (DOM), and indoleamines such as (+)-lysergic acid diethylamide (LSD) and psilocybin. Despite their differences in chemical structure, the two classes of hallucinogens produce remarkably similar subjective effects in humans, and induce cross-tolerance. The phenylalkylamine hallucinogens are selective 5-HT(2) receptor agonists, whereas the indoleamines are relatively non-selective for serotonin (5-HT) receptors. There is extensive evidence, from both animal and human studies, that the characteristic effects of hallucinogens are mediated by interactions with the 5-HT(2A) receptor. Nevertheless, there is also evidence that interactions with other receptor sites contribute to the psychopharmacological and behavioral effects of the indoleamine hallucinogens. This article reviews the evidence demonstrating that the effects of indoleamine hallucinogens in a variety of animal behavioral paradigms are mediated by both 5-HT(2) and non-5-HT(2) receptors.

Halberstadt, A. L., & Geyer, M.A. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 61(3), 364-381. http://dx.doi.org/10.1016/j.neuropharm.2011.01.017
Link to full text

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

Abstract

Context: Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer.

Objective: To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and reactive anxiety.

Design: A double-blind, placebo-controlled study of patients with advanced-stage cancer and anxiety, with subjects acting as their own control, using a moderate dose (0.2 mg/kg) of psilocybin.

Setting: A clinical research unit within a large public sector academic medical center.

Participants: Twelve adults with advanced-stage cancer and anxiety.

Main Outcome Measures: In addition to monitoring safety and subjective experience before and during experimental treatment sessions, follow-up data including results from the Beck Depression Inventory, Profile of Mood States, and State-Trait Anxiety Inventory were collected unblinded for 6 months after treatment.

Results: Safe physiological and psychological responses were documented during treatment sessions. There were no clinically significant adverse events with psilocybin. The State-Trait Anxiety Inventory trait anxiety subscale demonstrated a significant reduction in anxiety at 1 and 3 months after treatment. The Beck Depression Inventory revealed an improvement of mood that reached significance at 6 months; the Profile of Mood States identified mood improvement after treatment with psilocybin that approached but did not reach significance.

Conclusions: This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety. Some of the data revealed a positive trend toward improved mood and anxiety. These results support the need for more research in this long-neglected field.

Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. Archives of General Psychiatry, 68(1), 71-78. http://dx.doi.org/10.1001/archgenpsychiatry.2010.116
Link to full text

Exploring the impact of ketamine on the experience of illusory body ownership

Abstract

Background: Our sense of body ownership is profound and familiar, yet it may be misleading. In the rubber-hand illusion, synchronous tactile and visual stimulation lead to the experience that a rubber hand is actually one’s own. This illusion is emer in schizophrenia. Given the evidence that ketamine, a noncompetitive N-methyl-D-aspartate antagonist reproduces symptoms of schizophrenia, we sought to determine whether the rubber-hand illusion is augmented by ketamine.

Methods: We studied 15 healthy volunteers in a within-subjects placebo-controlled study. All volunteers carried out two versions of the rubber-hand task, each under both placebo and ketamine infusions. In one task, they saw a rubber hand being stroked in synchrony with tactile stimulation of their real, hidden hand. In the other, stroking of the real and rubber hands was asynchronous. We recorded subjective changes in sense of ownership, as well as participants’ ability to localize their hidden hand.

Results: Ketamine was associated with significant increases in subjective measures of the illusion and in hand mislocalization. Although asynchronous visuotactile stimulation attenuates the strength of the illusion during both placebo and ketamine, there remained a significant illusory effect during asynchronous visuotactile stimulation under ketamine compared with placebo. The strength of the illusion during asynchronous visuotactile stimulation correlated with other subjective effects of the drug.

Conclusions: Ketamine mimics the perturbed sense of body ownership seen in schizophrenia, suggesting that it produces a comparable alteration in integration of information across sensory domains and in the subjective and behavioral consequences of such integration.

Morgan, H. L., Turner, D. C., Corlett, P. R., Absalom, A. R., Adapa, R., Arana, F. S., … Fletcher, P. C. (2011). Exploring the impact of ketamine on the experience of illusory body ownership. Biological Psychiatry, 69(1), 35-41. http://dx.doi.org/10.1016/j.biopsych.2010.07.032
Link to full text

Characterization of behavioral and endocrine effects of LSD on zebrafish

Abstract

Lysergic acid diethylamide (LSD) is a potent hallucinogenic drug that strongly affects animal and human behavior. Although adult zebrafish (Danio rerio) are emerging as a promising neurobehavioral model, the effects of LSD on zebrafish have not been investigated previously. Several behavioral paradigms (the novel tank, observation cylinder, light–dark box, open field, T-maze, social preference and shoaling tests), as well as modern video-tracking tools and whole-body cortisol assay were used to characterize the effects of acute LSD in zebrafish. While lower doses (5–100 μg/L) did not affect zebrafish behavior, 250 μg/L LSD increased top dwelling and reduced freezing in the novel tank and observation cylinder tests, also affecting spatiotemporal patterns of activity (as assessed by 3D reconstruction of zebrafish traces and ethograms). LSD evoked mild thigmotaxis in the open field test, increased light behavior in the light–dark test, reduced the number of arm entries and freezing in the T-maze and social preference test, without affecting social preference. In contrast, LSD affected zebrafish shoaling (increasing the inter-fish distance in a group), and elevated whole-body cortisol levels. Overall, our findings show sensitivity of zebrafish to LSD action, and support the use of zebrafish models to study hallucinogenic drugs of abuse.

Grossman, L., Utterback, E., Stewarta, A., Gaikwada, S., Chunga, K. M., Suciua, C., … Kalueff, A. V. (2010). Characterization of behavioral and endocrine effects of LSD on zebrafish. Behavioural Brain Research, 214(2), 277-284. http://dx.doi.org/10.1016/j.bbr.2010.05.039
Link to full text

30 April - Q&A with Rick Strassman

X